160 related articles for article (PubMed ID: 19621142)
1. [Tigecycline: a systematic review of clinical experience during first years of prescription].
Diomedi P A
Rev Chilena Infectol; 2009 Apr; 26(2):114-25. PubMed ID: 19621142
[TBL] [Abstract][Full Text] [Related]
2. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
Bassetti M; McGovern PC; Wenisch C; Meyer RD; Yan JL; Wible M; Rottinghaus ST; Quintana A
Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
[TBL] [Abstract][Full Text] [Related]
3. Establishing the role of tigecycline in an era of antimicrobial resistance.
Schafer JJ; Goff DA
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
[TBL] [Abstract][Full Text] [Related]
4. Tigecycline: a glycylcycline antimicrobial agent.
Doan TL; Fung HB; Mehta D; Riska PF
Clin Ther; 2006 Aug; 28(8):1079-1106. PubMed ID: 16982286
[TBL] [Abstract][Full Text] [Related]
5. [The yield of tigecycline in the treatment of community-acquired pneumonia].
Cilli A
Tuberk Toraks; 2013; 61(2):155-61. PubMed ID: 23875595
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline: an update.
Stein GE; Babinchak T
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline: an antibiotic for the twenty-first century.
Dryden M
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii3-4. PubMed ID: 23772044
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of SSTI and role of tigecycline].
Concia E
Infez Med; 2009 Sep; 17 Suppl 4():64-76. PubMed ID: 20428022
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the efficacy and safety of tigecycline for treatment of respiratory tract infections: systematic review of literature].
Moya Cordero P; Ruiz-Aragón J; Molina Linde JM; Márquez-Peláez S; Motiva Sánchez V
Rev Chilena Infectol; 2013 Dec; 30(6):591-7. PubMed ID: 24522299
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
[TBL] [Abstract][Full Text] [Related]
11. Tigecycline: a new treatment option for intra-abdominal infections.
Menichetti F
J Chemother; 2009 Jul; 21 Suppl 1():36-8. PubMed ID: 19622449
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization.
Falagas ME; Metaxas EI
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):913-23. PubMed ID: 19803699
[TBL] [Abstract][Full Text] [Related]
13. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry.
Curcio D; Fernández F; Cané A; Barcelona L; Stamboulian D
Braz J Infect Dis; 2008 Jun; 12(3):198-201. PubMed ID: 18833403
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
Grolman DC
Int J Infect Dis; 2007 May; 11 Suppl 1():S7-15. PubMed ID: 17603950
[TBL] [Abstract][Full Text] [Related]
15. Is tigecycline drug of choice for cIAI and cSSTI?
Hosgor-Limoncu M
Int J Clin Pract; 2013 Jun; 67(6):492-3. PubMed ID: 23679901
[No Abstract] [Full Text] [Related]
16. [Uncertainties in the therapy of infectious diseases].
Heimann D
Dtsch Med Wochenschr; 2014 Nov; 139 Suppl 3():S82. PubMed ID: 25429535
[No Abstract] [Full Text] [Related]
17. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
[TBL] [Abstract][Full Text] [Related]
18. An essential requirement for the licensing of new antibiotics is the provision of data on efficacy and safety obtained from clinical trials in which patients are randomized to receive either the experimental drug or a comparator antibiotic regarded as a standard treatment option. Preface.
Johnson AP; Leibovici L
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii1. PubMed ID: 23930279
[No Abstract] [Full Text] [Related]
19. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies.
Montravers P; Bassetti M; Dupont H; Eckmann C; Heizmann WR; Guirao X; García MS; Capparella MR; Simoneau D; Bodmann KF
J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii15-24. PubMed ID: 23772042
[TBL] [Abstract][Full Text] [Related]
20. Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital.
Avkan-Oguz V; Yapar N; Alp-Cavus S; Demir Onder K; Aktas E; Gulay Z; Cakır N
Int J Clin Pract; 2013 Jun; 67(6):505-11. PubMed ID: 23679904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
